Finance

Lists
GUD:TSE
Knight Therapeutics Inc
10,83 CA$
+0,93%
(+0,10) 1D
9 ოქტ, 16:00:00 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for GUD...
Open
10,66 CA$
High
11,00 CA$
Low
10,40 CA$
Mkt. cap
1,06 მლრდ.
Avg. vol.
80,42 ათ.
Volume
76,84 ათ.
P/E ratio
72,21
52-wk high
11,00 CA$
52-wk low
5,66 CA$
EPS
0,15 CA$
Beta
-0,07
Shares outstanding
98,23 მლნ.
No. of employees
830
Open
10,66 CA$
High
11,00 CA$
Low
10,40 CA$
Mkt. cap
1,06 მლრდ.
Avg. vol.
80,42 ათ.
Volume
76,84 ათ.
P/E ratio
72,21
52-wk high
11,00 CA$
52-wk low
5,66 CA$
EPS
0,15 CA$
Beta
-0,07
Shares outstanding
98,23 მლნ.
No. of employees
830
News stories
From web sources and news partners
Profile
Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019. Wikipedia
About Knight Therapeutics Inc
CEO-
Employees830
Founded2014
Headquartersმონრეალი, კვებეკი, კანადა
SectorPharmaceutical industry
Last report
6 აგვ. 2026
Fiscal period
Q2 2026
-0,03 CA$ /
0,00%miss
Revenue / Est. (CAD)
144,21 მლნ. / 128,90 მლნ.
+11,88%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
121,55 მლნ.
133,11 მლნ.
148,44 მლნ.
144,21 მლნ.
Cost of goods sold
65,74 მლნ.
68,38 მლნ.
79,33 მლნ.
74,60 მლნ.
Cost of revenue
65,74 მლნ.
68,38 მლნ.
79,33 მლნ.
74,60 მლნ.
Research and development expenses
8,69 მლნ.
9,22 მლნ.
9,41 მლნ.
10,56 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,02 მლნ.
35,45 მლნ.
34,45 მლნ.
36,64 მლნ.
Operating expense
55,16 მლნ.
58,51 მლნ.
58,53 მლნ.
60,66 მლნ.
Total operating expenses
120,90 მლნ.
126,90 მლნ.
137,86 მლნ.
135,25 მლნ.
Operating income
646,00 ათ.
6,21 მლნ.
10,58 მლნ.
8,96 მლნ.
Other non operating income
-271,00 ათ.
329,00 ათ.
4,17 მლნ.
-487,00 ათ.
EBT including unusual items
-1,92 მლნ.
11,22 მლნ.
14,18 მლნ.
-2,10 მლნ.
EBT excluding unusual items
2,24 მლნ.
1,57 მლნ.
15,50 მლნ.
7,21 მლნ.
Income tax expense
1,87 მლნ.
2,37 მლნ.
1,01 მლნ.
1,26 მლნ.
Effective tax rate
-97,76%
21,12%
7,14%
-59,82%
Other operating expenses
-
-
-
-
Net income
-3,79 მლნ.
8,85 მლნ.
13,17 მლნ.
-3,36 მლნ.
Net profit margin
-3,12%
6,65%
8,87%
-2,33%
Earnings per share
-0,02
0,10
0,14
-0,03
Interest and investment income
1,11 მლნ.
1,22 მლნ.
952,00 ათ.
901,00 ათ.
Interest expense
-2,37 მლნ.
-3,92 მლნ.
-2,64 მლნ.
-2,12 მლნ.
Net interest expenses
-1,26 მლნ.
-2,70 მლნ.
-1,69 მლნ.
-1,22 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
18,41 მლნ.
16,47 მლნ.
26,77 მლნ.
23,97 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები